Clinical Assessment of Topiramate Therapy in Patients With Migrainous Vertigo

Göde, Sercan; Çelebisoy, Neşe; Kirazlı, Tayfun; Akyuz, Aycan; Bilgen, Cem; Karapolat, Hale; Şirin, Hadiye; Gökçay, Figen

doi:10.1111/j.1526-4610.2009.01496.x

Cited by 48 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an investigation by Gode et al, not included in our analysis due to nonevaluable data, reductions in frequency and intensity of headache and vertigo attacks were observed with topiramate use after 24 weeks. 46 However, its use was limited by side effects: paresthesia (19/30), fatigue (11/30), memory/concentration issues (8/30), decreased appetite (14/30), and weight loss (4/30). Four patients discontinued treatment in this study due to adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Vestibular Migraine: A Systematic Review and Meta‐analysis

et al. 2020

View full text Add to dashboard Cite

Objective To assess the efficacy of the various therapies used for the prevention of vestibular migraine (VM). Methods Primary studies were identified though PubMed, Scopus, PsycINFO, and Cochrane Library by two independent investigators for articles published through April 2019. The search identified randomized comparison or observational studies pertaining to vestibular migraine treatment. Meta‐analysis was performed on pre‐ and posttreatment Dizziness Handicap Inventory, vertigo frequency, and percentage of perceived improvement. Results Literature search identified 13 studies that reported sufficient outcome measures to be included in the analysis. Patients with VM had a mean age of 43.3 years with female‐to‐male gender ratio of 2.1:1. Classes of therapeutic agents included antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, β‐blockers, serotonin and norepinephrine reuptake inhibitors, and vestibular rehabilitation. All treatment options that were analyzed demonstrated improvement in all of the outcome parameters, but due to significant heterogeneity and lack of standardized reporting on outcomes, establishment of preferred treatment modality could not be determined. Conclusions Various treatment modalities have been evaluated for preventative treatment of VM. Physician familiarity, patient comorbidities, and the side‐effect profiles of various interventions likely influence the selection of intervention. Future randomized controlled trials with restrictive inclusion criteria and generalizable standardized outcome measures will allow for more robust meta‐analyses and for more evidence‐based treatment of vestibular migraines. Laryngoscope, 131:186–194, 2021

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Vestibular Migraine: A Systematic Review and Meta‐analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Abortive therapy using antimigraine medications like triptans and antiemetics such as promethazine and meclizine has been thought to be helpful [28,29]. Prophylactic therapy involves using anti-migraine medications with anecdotal preference for verapamil, topiramate, and lamotrigine [29,30]. A recent study showed significantly increased benefit in the treatment of vertigo in vestibular migraine patients using flunarizine in addition to betahistine, a finding that supports the role of calcium channel dysregulation in the pathogenesis of vestibular migraine [31].…”

Section: Vestibular Migrainementioning

confidence: 95%

Migraine and Vertigo

Swaminathan

Smith

2014

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Vertigo and migraine are commonly co-occurring problems. The diagnostic criteria for vestibular migraine have recently been updated in the International Classification of Headache Disorders, 3rd edition (beta version), which allow better detection of this under-recognized condition. In many cases, a diagnosis of vestibular migraine will be established based on a typical history of concurrent migraine headache, photophobia, and/or migraine aura with the vertigo. Certain mimickers, such as Ménière's disease, likely exist on a pathophysiologic continuum with vestibular migraine. In our review, we provide an update on the salient literature regarding the diagnosis and management of this condition.

show abstract

“…A recent noncontrolled open study suggests that topiramate could also be effective for the preventive treatment of migrainous vertigo, even at a small dose of 50 mg/day [34 ]. In the large INTREPID study, topiramate 100 mg/day was unable to prevent the development of chronic daily headache in migraineurs with high frequency of attacks, although it was effective in reducing overall headache days [35 ].…”

Section: Pharmacological Treatmentmentioning

confidence: 97%